Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present AstraZeneca Plc (OTC: AZNCF).

Full DD Report for AZNCF

You must become a subscriber to view this report.


Recent News from (OTC: AZNCF)

Healthcare Net Gains Leaders For 2018 Are Glaxo, Sanofi, Merck, Owens, Novartis, And Pfizer Per Broker Targets
Actionable Conclusions (1-10): Analysts Predicted 3.18% To 23.18% Net Gains For Top Ten Healthcare Dogs By December 2018 Six of ten top dividend-yielding Healthcare dogs were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (They ...
Source: SeekingAlpha
Date: December, 29 2017 01:26
AstraZeneca Plc 2017 Q3 - Results - Earnings Call Slides
The following slide deck was published by AstraZeneca Plc in conjunction with their 2017 Q3 earnings Read more ...
Source: SeekingAlpha
Date: November, 10 2017 16:26
AstraZeneca (AZN) Presents At European Society For Medical Oncology Annual Congress - Slideshow
The following slide deck was published by AstraZeneca Group plc in conjunction with this Read more ...
Source: SeekingAlpha
Date: September, 11 2017 13:06
AstraZeneca (AZNCF)Presents At JP Morgan European Healthcare Conference - Slideshow
The following slide deck was published by AstraZeneca Plc in conjunction with this Read more ...
Source: SeekingAlpha
Date: June, 22 2017 13:15
Roche Is A Buy Even On Conservative Assumptions For Its Pipeline
I've recently discussed the key reasons I think Roche’s ( OTCQX:RHHBY ) guidance for 2017 is conservative, so in this article I will focus on a quantitative valuation of the company to show why I think Roche is an attractive investment if you believe in the ability of the company to d...
Source: SeekingAlpha
Date: March, 18 2017 01:06
Autoimmune Disease Vies With Cancer To Dominate The Class Of 2017
Given the stunning multiple sclerosis data seen with Roche’s (RHHBY) Ocrevus it could come as a surprise that this agent is not the biggest expected launch of 2017. That honor belongs to Sanofi (SNY)/Regeneron’s (REGN) dermatitis hopeful Dupixent, which thus also edges out Astra...
Source: SeekingAlpha
Date: January, 31 2017 14:53
AstraZeneca: What To Expect At FY 2016 Results
AstraZeneca ( OTCPK: AZNCF ), will report its full-year results for 2016 on 2nd February 2017. Shares of the company haven't done quite well over the past 6 months and they are currently trading not far from 52-week low, despite AstraZeneca is entering a critical phase with 4 key drugs which...
Source: SeekingAlpha
Date: January, 31 2017 10:09
Big Pharma Leads Healthcare Sector In Broker May Gains
Healthcare SML Dog Examination A stock paying a reliable, repeating dividend whose price has fallen to a point where it's yield (dividend/price) has grown higher than it's peers (here in the Healthcare sector) is tagged as a dividend dog. Thus, the highest yielding stocks in any collecti...
Source: SeekingAlpha
Date: May, 10 2016 12:13

 


About AstraZeneca Plc (OTC: AZNCF)

Logo for AstraZeneca Plc (OTC: AZNCF)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $82,278,278,100 - 03/16/2018
  • Issue and Outstanding: 1,252,333,000 - 08/30/2013

 


Recent Filings from (OTC: AZNCF)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 11 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 08 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 07 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 04 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 24 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 19 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 13 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 13 2018

 

 


Daily Technical Chart for (OTC: AZNCF)

Daily Technical Chart for (OTC: AZNCF)


Stay tuned for daily updates and more on (OTC: AZNCF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: AZNCF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AZNCF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of AZNCF and does not buy, sell, or trade any shares of AZNCF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/